China Regulatory Roundup: AZ Gains PD-L1 Green Light Ahead Of Roche
But Can China Take As Many As Eight More?
Executive Summary
Oncology continues to dominate new drug approvals in China as AstraZeneca gains the first clearance for a PD-L1 drug ahead of Roche. But there are as many as seven others in the class coming along, including from domestic firms Hengrui and CStone.